Glaukos Corp (GKOS) Stock Price, Quote & News

Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patient...

Industry: Medical Devices

Sector: Healthcare

Phone: 949 367 9600

Fax: 949 367 9984

Website: www.glaukos.com

Address:

One Glaukos Way, Aliso Viejo, United States

Kingofstocks0001 Jun. 8 at 1:41 PM

$GKOS let’s go!!!!!

0 · Reply

Adriana88 Jun. 7 at 7:55 PM

$GKOS

0 · Reply

Niddi Jun. 5 at 9:11 PM

$GKOS Current SP is the proof that it was heavily manipulated. How can these people manipulate the price so much easily? Corrupt market!

1 · Reply

Niddi Jun. 4 at 2:03 PM

$GKOS Obvious manipulation to drag it down to under $100.

0 · Reply

Sarcozuchus26 Jun. 2 at 10:18 PM

$GKOS What a bargain guys, jump in!

0 · Reply

JFDI Jun. 2 at 6:18 PM

$GKOS waking up?

0 · Reply

Niddi May. 29 at 6:42 PM

$GKOS This manipulation is shameful. From $147 to 102 in 10 days, despite the positive news!!!!!

1 · Reply

Kingofstocks0001 May. 26 at 7:47 PM

$GKOS crazy drop!!!

0 · Reply

Arcides May. 22 at 9:17 PM

$GKOS rekilled on no news

0 · Reply

Niddi May. 22 at 8:21 PM

$GKOS What happened here? Shorts?? News??

2 · Reply

Glaukos Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 1:00 PM EDT - 6 days ago

Glaukos Transcript: 46th Annual William Blair Growth Stock Conference

May 28, 2026, 12:00 PM EDT - 11 days ago

Glaukos Transcript: AGM 2026

2026-05-26T18:55:44.000Z - 13 days ago

Glaukos pullback due to concerns about iDose LCD, says William Blair

May 26, 2026, 1:30 PM EDT - 13 days ago

Glaukos Transcript: Stifel 2026 Virtual Ophthalmology Forum

2026-05-21T11:47:58.000Z - 18 days ago

Glaukos price target raised to $162 from $141 at BTIG

May 12, 2026, 7:00 AM EDT - 27 days ago

Glaukos Announces Participation in Upcoming Investor Conferences

May 1, 2026, 7:00 AM EDT - 5 weeks ago

Glaukos Slides: Investor presentation

2026-04-30T16:53:30.000Z - 5 weeks ago

Glaukos price target raised to $153 from $134 at Goldman Sachs

2026-04-30T16:01:03.000Z - 5 weeks ago

Glaukos price target raised to $170 from $160 at Stifel

2026-04-30T15:49:51.000Z - 5 weeks ago

Glaukos price target raised to $140 from $120 at JPMorgan

2026-04-30T12:55:10.000Z - 5 weeks ago

Glaukos price target raised to $136 from $127 at Needham

2026-04-30T12:38:00.000Z - 5 weeks ago

Glaukos price target raised to $141 from $131 at BTIG

2026-04-30T11:45:13.000Z - 5 weeks ago

Glaukos price target raised to $140 from $135 at Citi

2026-04-29T21:40:59.000Z - 5 weeks ago

Glaukos reports Q1 EPS (18c), consensus (28c)

2026-04-29T21:40:03.000Z - 5 weeks ago

Glaukos sees FY26 revenue $620M-$635M, consensus $614.4M

Apr 29, 2026, 4:30 PM EDT - 5 weeks ago

Glaukos Earnings Call Transcript: Q1 2026

Apr 29, 2026, 4:30 PM EDT - 5 weeks ago

Glaukos Earnings release: Q1 2026

Apr 29, 2026, 4:30 PM EDT - 5 weeks ago

Glaukos Quarterly report: Q1 2026

Apr 29, 2026, 4:05 PM EDT - 5 weeks ago

Glaukos Announces First Quarter 2026 Financial Results

Apr 16, 2026, 8:00 AM EDT - 7 weeks ago

Glaukos Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 7 weeks ago

Glaukos Proxy statement: Proxy filing

Apr 16, 2026, 7:00 AM EDT - 7 weeks ago

Glaukos Announces the Release of its 2025 Sustainability Report

2026-04-15T20:15:44.000Z - 7 weeks ago

Glaukos receives permanent J-code for Epioxa

Apr 15, 2026, 4:05 PM EDT - 7 weeks ago

Glaukos Receives Permanent J-code for Epioxa™

Apr 8, 2026, 7:00 AM EDT - 2 months ago

Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29

2026-04-07T11:01:34.000Z - 2 months ago

Glaukos price target raised to $135 from $125 at Citi

$Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting$

Apr 6, 2026, 7:00 AM EDT - 2 months ago

Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

2026-03-19T11:12:04.000Z - 2 months ago

Glaukos announces commercial availability of Epioxa HD/Epioxa

Mar 19, 2026, 7:00 AM EDT - 2 months ago

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

2026-03-12T20:13:14.000Z - 3 months ago

Glaukos management to meet with Piper Sandler

Mar 5, 2026, 7:00 AM EST - 3 months ago

Glaukos Slides: Investor presentation

2026-02-18T12:20:55.000Z - 3 months ago

Glaukos price target raised to $127 from $125 at Needham

2026-02-18T11:31:03.000Z - 3 months ago

Glaukos price target raised to $135 from $122 at Wells Fargo

Feb 17, 2026, 4:30 PM EST - 3 months ago

Glaukos Earnings Call Transcript: Q4 2025

Feb 17, 2026, 4:30 PM EST - 3 months ago

Glaukos Annual report: Q4 2025

Feb 17, 2026, 4:30 PM EST - 3 months ago

Glaukos Earnings release: Q4 2025

2026-02-17T21:12:49.000Z - 3 months ago

Glaukos reports Q4 adjusted EPS (28c), consensus (30c)

Feb 17, 2026, 4:05 PM EST - 3 months ago

Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

Jan 28, 2026, 7:00 AM EST - 4 months ago

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

Jan 20, 2026, 7:00 AM EST - 4 months ago

Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17

Jan 13, 2026, 7:30 PM EST - 5 months ago

Glaukos Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 4:05 PM EST - 5 months ago

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

Jan 12, 2026, 4:00 PM EST - 5 months ago

Glaukos Slides: Investor presentation

Dec 16, 2025, 7:00 AM EST - 6 months ago

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

Dec 3, 2025, 1:45 PM EST - 6 months ago

Glaukos Transcript: Citi Annual Global Healthcare Conference 2025

Nov 18, 2025, 11:00 AM EST - 7 months ago

Glaukos Transcript: Stephens Annual Investment Conference

Nov 12, 2025, 1:20 PM EST - 7 months ago

Glaukos Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 10:15 AM EST - 7 months ago

Glaukos Transcript: UBS Global Healthcare Conference 2025

Nov 9, 2025, 6:00 PM EST - 7 months ago

Glaukos Slides: Corporate Presentation

Oct 29, 2025, 4:30 PM EDT - 7 months ago

Glaukos Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 7 months ago

Glaukos Quarterly report: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 7 months ago

Glaukos Earnings release: Q3 2025

Oct 29, 2025, 4:05 PM EDT - 7 months ago

Glaukos Announces Third Quarter 2025 Financial Results

Oct 20, 2025, 7:10 AM EDT - 8 months ago

US FDA approves Glaukos' new eye therapy

Oct 20, 2025, 7:00 AM EDT - 8 months ago

Glaukos Announces FDA Approval of Epioxa™

Oct 14, 2025, 7:00 AM EDT - 8 months ago

Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting

Oct 8, 2025, 7:00 AM EDT - 8 months ago

Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29

Sep 25, 2025, 4:05 PM EDT - 9 months ago

Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

Sep 3, 2025, 10:15 AM EDT - 9 months ago

Glaukos Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 13, 2025, 7:00 AM EDT - 10 months ago

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Jul 30, 2025, 4:30 PM EDT - 11 months ago

Glaukos Earnings Call Transcript: Q2 2025

Jul 30, 2025, 4:30 PM EDT - 11 months ago

Glaukos Quarterly report: Q2 2025

Jul 30, 2025, 4:30 PM EDT - 11 months ago

Glaukos Earnings release: Q2 2025

Jul 30, 2025, 4:05 PM EDT - 11 months ago

Glaukos Announces Second Quarter 2025 Financial Results

Jul 9, 2025, 7:00 AM EDT - 11 months ago

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

Jun 25, 2025, 4:05 PM EDT - 1 year ago

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

Jun 4, 2025, 8:45 AM EDT - 1 year ago

Glaukos Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 1:40 PM EDT - 1 year ago

Glaukos Transcript: 45th Annual William Blair Growth Stock Conference

May 27, 2025, 12:30 PM EDT - 1 year ago

Glaukos Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 14, 2025, 7:00 AM EDT - 1 year ago

Glaukos Slides: Investor Presentation

Apr 30, 2025, 4:30 PM EDT - 1 year ago

Glaukos Earnings Call Transcript: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

Glaukos Quarterly report: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

Glaukos Earnings release: Q1 2025

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Glaukos Announces First Quarter 2025 Financial Results

$Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting$

Apr 23, 2025, 7:00 AM EDT - 1 year ago

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 16, 2025, 7:00 AM EDT - 1 year ago

Glaukos Announces the Release of its 2024 Sustainability Report

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Glaukos Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Glaukos Proxy statement: Proxy Filing

Apr 9, 2025, 7:00 AM EDT - 1 year ago

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

Mar 11, 2025, 7:00 AM EDT - 1 year ago

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Feb 24, 2025, 7:00 AM EST - 1 year ago

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Feb 20, 2025, 4:30 PM EST - 1 year ago

Glaukos Earnings Call Transcript: Q4 2024

Feb 20, 2025, 4:30 PM EST - 1 year ago

Glaukos Annual report: Q4 2024

Feb 20, 2025, 4:30 PM EST - 1 year ago

Glaukos Earnings release: Q4 2024

Feb 20, 2025, 4:05 PM EST - 1 year ago

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Jan 23, 2025, 7:00 AM EST - 1 year ago

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Jan 14, 2025, 8:15 PM EST - 1 year ago

Glaukos Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 8:15 PM EST - 1 year ago

Glaukos Slides: FY 2025

Jan 14, 2025, 4:05 PM EST - 1 year ago

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Jan 14, 2025, 7:00 AM EST - 1 year ago

Glaukos Slides: Investor Presentation

Dec 23, 2024, 7:00 AM EST - 1 year ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Dec 17, 2024, 7:00 AM EST - 1 year ago

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Dec 5, 2024, 9:30 AM EST - 1 year ago

Glaukos Transcript: Citi's 2024 Global Healthcare Conference

Dec 4, 2024, 1:00 PM EST - 1 year ago

Glaukos Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 10:00 AM EST - 1 year ago

Glaukos Transcript: Stephens 26th Annual Investment Conference | NASH2024

Nov 19, 2024, 12:40 PM EST - 1 year ago

Glaukos Transcript: Stifel 2024 Healthcare Conference

Nov 4, 2024, 4:30 PM EST - 1 year ago

Glaukos Earnings Call Transcript: Q3 2024

Nov 4, 2024, 4:30 PM EST - 1 year ago

Glaukos Quarterly report: Q3 2024

Nov 4, 2024, 4:30 PM EST - 1 year ago

Glaukos Earnings release: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

Glaukos Announces Third Quarter 2024 Financial Results

Oct 16, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Sep 23, 2024, 1:30 AM EDT - 1 year ago

Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

Sep 5, 2024, 12:20 PM EDT - 1 year ago

Glaukos Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 4, 2024, 12:45 PM EDT - 1 year ago

Glaukos Transcript: 2024 Wells Fargo Healthcare Conference

Jul 31, 2024, 4:30 PM EDT - 2 years ago

Glaukos Earnings Call Transcript: Q2 2024

Jul 31, 2024, 4:30 PM EDT - 2 years ago

Glaukos Quarterly report: Q2 2024

Jul 31, 2024, 4:30 PM EDT - 2 years ago

Glaukos Earnings release: Q2 2024

Jul 31, 2024, 4:05 PM EDT - 2 years ago

Glaukos Announces Second Quarter 2024 Financial Results

Jul 10, 2024, 7:00 AM EDT - 2 years ago

Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

Jun 18, 2024, 12:45 PM EDT - 2 years ago

Glaukos Transcript: 2024 Truist Securities MedTech Conference

Jun 14, 2024, 7:00 AM EDT - 2 years ago

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

Jun 5, 2024, 1:40 PM EDT - 2 years ago

Glaukos Transcript: The 44th Annual William Blair Growth Stock Conference

May 30, 2024, 12:00 PM EDT - 2 years ago

Glaukos Transcript: AGM 2024

May 1, 2024, 4:30 PM EDT - 2 years ago

Glaukos Earnings Call Transcript: Q1 2024

May 1, 2024, 4:30 PM EDT - 2 years ago

Glaukos Quarterly report: Q1 2024

May 1, 2024, 4:30 PM EDT - 2 years ago

Glaukos Earnings release: Q1 2024

May 1, 2024, 4:05 PM EDT - 2 years ago

Glaukos Announces First Quarter 2024 Financial Results

Apr 16, 2024, 4:05 PM EDT - 2 years ago

Glaukos Announces the Release of its 2023 Sustainability Report

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Glaukos Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Glaukos Proxy statement: Proxy Filing

Apr 10, 2024, 7:00 AM EDT - 2 years ago

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

$Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting$

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Feb 21, 2024, 4:30 PM EST - 2 years ago

Glaukos Earnings Call Transcript: Q4 2023

Feb 21, 2024, 4:30 PM EST - 2 years ago

Glaukos Annual report: Q4 2023

Feb 21, 2024, 4:30 PM EST - 2 years ago

Glaukos Earnings release: Q4 2023

Feb 21, 2024, 4:05 PM EST - 2 years ago

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

Jan 31, 2024, 7:00 AM EST - 2 years ago

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

Jan 10, 2024, 7:00 AM EST - 2 years ago

Glaukos Slides: Investor Presentation

Jan 9, 2024, 8:15 PM EST - 2 years ago

Glaukos Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 9, 2024, 8:15 PM EST - 2 years ago

Glaukos Slides: FY 2024

Jan 9, 2024, 7:00 AM EST - 2 years ago

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance

Kingofstocks0001 Jun. 8 at 1:41 PM

$GKOS let’s go!!!!!

0 · Reply

Adriana88 Jun. 7 at 7:55 PM

$GKOS

0 · Reply

Niddi Jun. 5 at 9:11 PM

$GKOS Current SP is the proof that it was heavily manipulated. How can these people manipulate the price so much easily? Corrupt market!

1 · Reply

Niddi Jun. 4 at 2:03 PM

$GKOS Obvious manipulation to drag it down to under $100.

0 · Reply

Sarcozuchus26 Jun. 2 at 10:18 PM

$GKOS What a bargain guys, jump in!

0 · Reply

JFDI Jun. 2 at 6:18 PM

$GKOS waking up?

0 · Reply

Niddi May. 29 at 6:42 PM

$GKOS This manipulation is shameful. From $147 to 102 in 10 days, despite the positive news!!!!!

1 · Reply

Kingofstocks0001 May. 26 at 7:47 PM

$GKOS crazy drop!!!

0 · Reply

Arcides May. 22 at 9:17 PM

$GKOS rekilled on no news

0 · Reply

Niddi May. 22 at 8:21 PM

$GKOS What happened here? Shorts?? News??

2 · Reply

Kingofstocks0001 May. 22 at 12:13 AM

$GKOS sinking!!!!! Nooooooooooo

0 · Reply

anachartanalyst May. 21 at 10:01 AM

$GKOS https://anachart.com/wp-content/uploads/2026/05/1779357670_soc-img.jpg

0 · Reply

squeezeanalyst May. 20 at 11:50 PM

speaking of Ws... how many do you see in this one? $GKOS

0 · Reply

NVDAMillionaire May. 13 at 9:02 PM

$GKOS Excellent article that nails exactly where GKOS stands right now. So if you want to update your GKOS knowledge or get acquainted with GKOS, this is a must read. https://everyticker.com/quote/GKOS/analysis/idose-tr-and-epioxa-glaukos-s-path-from-ophthalmic-pioneer-to-profitable-rare-disease-platform-nyse-gkos

0 · Reply

Synaptric May. 13 at 1:31 PM

15 good-looking healthcare charts in this sad, narrow, semi/tech-only market. $XLV $CNC $GKOS $LNTH $JAZZ

0 · Reply

SuperGreenToday May. 4 at 7:58 PM

$GKOS Share Price: $135.98 Contract Selected: Oct 16, 2026 $135 Calls Buy Zone: $15.39 – $19.01 Target Zone: $28.15 – $34.41 Potential Upside: 73% ROI Time to Expiration: 164 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply